Serum neurofilament-light concentration and real-world outcome in MS

Prognostication in multiple sclerosis (MS) remains challenging. Biomarkers capable of providing this information at diagnosis would be valuable in shaping therapeutic decisions. Measurement of neurofilament light (NfL) has shown promise in predicting clinical outcomes in established MS, but its ability to predict outcomes in real-world cohorts at diagnosis requires further validation.

Source link

Related posts

The cerebellar histiocytosis: Progressive ataxia is not always a genetic disease


In vivo evidence of remote neural degeneration in the lumbar enlargement after cervical injury


Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World